Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

Market Overview - The Acute Myeloid Leukemia (AML) market was valued at USD 2.1 billion in 2023 and is projected to grow at a CAGR of 10.7% from 2024 to 2032, driven by advancements in research, government initiatives, and increasing prevalence of AML [1][2] - In 2023, there were approximately 20,380 new cases of AML reported in the U.S., indicating a rising patient pool due to an aging population [1] Treatment Segments - The chemotherapy segment generated the largest market revenue of USD 1.3 billion in 2023, as it effectively targets rapidly dividing AML cells [2] - Approximately 60-70% of adults with AML can expect to achieve complete remission after appropriate chemotherapy, highlighting its efficacy [2] Company Developments - Actinium Pharmaceuticals presented preclinical data at the 2024 EHA Congress showing that Actimab-A in combination with menin inhibitors significantly enhances AML cell death compared to monotherapy [3][4] - Actimab-A targets CD33, a marker prevalent in AML patients, and is designed for combination therapies with other agents, including chemotherapy and targeted therapies [5][6] Menin Inhibitors - Menin inhibitors are being developed for AML patients with KMT2A rearrangements and NPM1 mutations, which affect approximately 10% and 30% of AML patients, respectively [6] - Revumenib and ziftomenib are notable menin inhibitors, with revumenib expected to have PDUFA data by September 2024 and ziftomenib currently in a registration Phase 2 trial [6][7] Clinical Trials and Future Prospects - Kura Oncology has completed enrollment for its Phase 2 trial of ziftomenib in relapsed or refractory NPM1-mutant AML, with topline data expected in early 2025 [7][8] - The combination of Actimab-A with menin inhibitors shows promise for improving treatment outcomes across various AML settings, including frontline and relapsed cases [6][8]